CL2023001408A1 - Terapias de inhibición de ezh2 para cánceres de próstata con mutación del receptor de andrógenos - Google Patents
Terapias de inhibición de ezh2 para cánceres de próstata con mutación del receptor de andrógenosInfo
- Publication number
- CL2023001408A1 CL2023001408A1 CL2023001408A CL2023001408A CL2023001408A1 CL 2023001408 A1 CL2023001408 A1 CL 2023001408A1 CL 2023001408 A CL2023001408 A CL 2023001408A CL 2023001408 A CL2023001408 A CL 2023001408A CL 2023001408 A1 CL2023001408 A1 CL 2023001408A1
- Authority
- CL
- Chile
- Prior art keywords
- androgen receptor
- prostate cancers
- ezh2 inhibition
- inhibition therapies
- receptor mutated
- Prior art date
Links
- 208000000236 Prostatic Neoplasms Diseases 0.000 title abstract 2
- 102000001307 androgen receptors Human genes 0.000 title abstract 2
- 108010080146 androgen receptors Proteins 0.000 title abstract 2
- 230000005764 inhibitory process Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- CAAWBLRXQXMGHV-UHFFFAOYSA-N 7-chloro-2-[4-(3-methoxyazetidin-1-yl)cyclohexyl]-2,4-dimethyl-N-[(6-methyl-4-methylsulfanyl-2-oxo-1H-pyridin-3-yl)methyl]-1,3-benzodioxole-5-carboxamide Chemical compound ClC1=CC(=C(C2=C1OC(O2)(C)C1CCC(CC1)N1CC(C1)OC)C)C(=O)NCC=1C(NC(=CC=1SC)C)=O CAAWBLRXQXMGHV-UHFFFAOYSA-N 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 abstract 1
- 229960004671 enzalutamide Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
En el presente documento se proporcionan métodos para tratar el cáncer de próstata que tiene al menos una mutación AR patógena usando 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-N-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida, o una sal del mismo farmacéuticamente aceptable, solo o en combinación con una cantidad terapéuticamente efectiva de un inhibidor de la señalización del receptor de andrógenos (ARSI) tal como enzalutamida.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063115165P | 2020-11-18 | 2020-11-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023001408A1 true CL2023001408A1 (es) | 2024-01-12 |
Family
ID=79024100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023001408A CL2023001408A1 (es) | 2020-11-18 | 2023-05-16 | Terapias de inhibición de ezh2 para cánceres de próstata con mutación del receptor de andrógenos |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230414593A1 (es) |
| EP (1) | EP4247371A1 (es) |
| JP (1) | JP2023549564A (es) |
| KR (1) | KR20230110527A (es) |
| CN (1) | CN116600804A (es) |
| AU (1) | AU2021382606A1 (es) |
| CA (1) | CA3199421A1 (es) |
| CL (1) | CL2023001408A1 (es) |
| IL (1) | IL303025A (es) |
| MX (1) | MX2023005840A (es) |
| WO (1) | WO2022109106A1 (es) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS65621B1 (sr) * | 2018-04-18 | 2024-07-31 | Constellation Pharmaceuticals Inc | Modulatori enzima koji modifikuju metil, sastavi i njihova upotreba |
-
2021
- 2021-11-18 EP EP21827282.1A patent/EP4247371A1/en active Pending
- 2021-11-18 CN CN202180077565.8A patent/CN116600804A/zh active Pending
- 2021-11-18 IL IL303025A patent/IL303025A/en unknown
- 2021-11-18 AU AU2021382606A patent/AU2021382606A1/en active Pending
- 2021-11-18 CA CA3199421A patent/CA3199421A1/en active Pending
- 2021-11-18 MX MX2023005840A patent/MX2023005840A/es unknown
- 2021-11-18 JP JP2023529941A patent/JP2023549564A/ja active Pending
- 2021-11-18 WO PCT/US2021/059847 patent/WO2022109106A1/en active Application Filing
- 2021-11-18 KR KR1020237017778A patent/KR20230110527A/ko unknown
- 2021-11-18 US US18/037,120 patent/US20230414593A1/en active Pending
-
2023
- 2023-05-16 CL CL2023001408A patent/CL2023001408A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022109106A1 (en) | 2022-05-27 |
| EP4247371A1 (en) | 2023-09-27 |
| AU2021382606A9 (en) | 2024-08-08 |
| CN116600804A (zh) | 2023-08-15 |
| MX2023005840A (es) | 2023-06-02 |
| CA3199421A1 (en) | 2022-05-27 |
| KR20230110527A (ko) | 2023-07-24 |
| AU2021382606A1 (en) | 2023-06-22 |
| IL303025A (en) | 2023-07-01 |
| US20230414593A1 (en) | 2023-12-28 |
| JP2023549564A (ja) | 2023-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022012780A (es) | Inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras) triciclicos fusionados. | |
| MX2021014177A (es) | Inhibidores de kras con la mutacion de glicina a cisteina en el codon 12 (g12c) y usos de los mismos. | |
| MY196582A (en) | PD-1/PD-L1 Inhibitors | |
| PH12021500004A1 (en) | Pd-1/pd-l1 inhibitors | |
| MX2018013848A (es) | Combinacion de anticuerpos anti-pd-1s y radiacion para tratar cancer. | |
| MX2023011856A (es) | Tratamientos conjuntos que usan inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) para el tratamiento de cáncer. | |
| MX2024006123A (es) | Triptaminas especificas para usarse en el tratamiento de trastornos de estado de animo. | |
| CL2022002515A1 (es) | Compuestos de tetralina y tetrahidroquinolina como inhibidores de hif-2alfa | |
| ECSP066362A (es) | Inhibidores de quinesina mitótica. | |
| CO2022001480A2 (es) | Inhibición de ezh2 en tratamientos combinados para el tratamiento del cáncer | |
| MX2023011853A (es) | Tratamientos conjuntos que usan inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) para el tratamiento del cáncer. | |
| MX2019012176A (es) | Metodos de combinacion de chk1(sra737)/parpi para inhibir el crecimiento tumoral. | |
| ECSP066458A (es) | 6-[(sustituido)fenil]triazolopirimidinas como agentes anticancer | |
| CO2024009571A2 (es) | Inhibidores de parp1 | |
| PH12015502260A1 (en) | C. novyi for the treatment of solid tumors in humans | |
| MX2022008099A (es) | Tratamiento para el cancer con inhibidores de cdk12/13. | |
| CR20240059A (es) | Compuestos tricíclicos como inhibidores de kras. | |
| CL2021001638A1 (es) | Tratamiento del cáncer con docetaxel controlando los niveles plasmáticos máximos | |
| WO2023287730A8 (en) | Tricyclic compounds | |
| AR126101A1 (es) | Heterociclos tricíclicos como inhibidores de fgfr | |
| MX2022004524A (es) | Tratamiento génico para la enfermedad de alzheimer. | |
| CL2023001408A1 (es) | Terapias de inhibición de ezh2 para cánceres de próstata con mutación del receptor de andrógenos | |
| MX2023005806A (es) | Tratamiento de cánceres con mutación en oncogen homologo al virus kirsten de sarcoma de rata (kras). | |
| MX2021015970A (es) | Terapia de combinacion con bloqueo de semaforina-4d (sema4d) y terapia de dc1. | |
| MX2024000406A (es) | Combinacion de inhibidores de puntos de control y un virus oncolitico para el tratamiento del cancer. |